featured
Efficacy and Safety of Methotrexate, Omalizumab, and Dupilumab for Bullous Pemphigoid in Patients Resistant to Oral Steroids
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of the European Academy of Dermatology and Venereology: JEADV
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Efficacy and safety of methotrexate, omalizumab and dupilumab for bullous pemphigoid in patients resistant or contraindicated to oral steroids. A monocentric real-life study
J Eur Acad Dermatol Venereol 2022 Feb 10;[EPub Ahead of Print], M Velin, PM Dugourd, A Sanchez, P Bahadoran, H Montaudié, T PasseronFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.